UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
CELL & GENE THERAPY

WuXi Biologics

W

WuXi Biologics

Cell & Gene TherapyShanghai, China
Visit Website

About WuXi Biologics

WuXi Biologics operates one of the largest open-access biologics platforms in the world, offering end-to-end services that take a molecule from concept through to commercial manufacture under a single contract research, development and manufacturing organisation.

Global CRDMO Platform

Founded in 2010 and headquartered in Shanghai, China, WuXi Biologics is listed on the Hong Kong Stock Exchange. The company's integrated model covers discovery, pre-clinical and clinical development, regulatory affairs support, and large-scale biologics manufacturing, spanning monoclonal antibodies, bispecifics, antibody-drug conjugates, fusion proteins, vaccines and cell and gene therapy modalities. Its WuXiUP platform is designed to compress biologics development timelines, enabling partners to move from gene to IND filing on an accelerated schedule.

The company maintains a global manufacturing network that includes facilities in China, Ireland, Germany, Singapore and the United States, giving clients commercial-scale GMP capacity across major regulatory jurisdictions. This geographic spread allows multinational pharmaceutical companies as well as emerging biotechs to access compliant manufacturing close to their primary markets.

Partnerships Across the Industry

WuXi Biologics serves a broad client base that includes global pharmaceutical majors, mid-sized biotechnology companies and academic spin-outs seeking external biologics expertise. The company's contract biologics manufacturing capacity has expanded significantly since its founding, and its client portfolio spans oncology, immunology, rare diseases and infectious disease, reflecting the therapy areas that have driven biologics growth over the past decade.

As a publicly traded CRDMO, WuXi Biologics publishes annual reports under Hong Kong Stock Exchange disclosure requirements, providing transparent financial and operational data for partners and investors. Its open-access philosophy, a founding principle, means the company does not compete with its clients by developing proprietary drugs, positioning it as a neutral partner across the industry.

Further information is available at wuxibiologics.com.

Similar Companies

More in Cell & Gene Therapy

S

Sartorius

Sartorius is one of the few life science companies to have grown continuously for over 150 years, tracing its origins to Göttingen, Germany, in 1870. Today it serves as a critical partner to biopharma manufacturers and research laboratories worldwide, supplying the equipment, consumables, and data analytics tools that underpin the development and production of biological medicines. Bioprocess Solutions: The Industrial Core The company's Bioprocess Solutions division is its largest business segment, focused on upstream and downstream bioprocessing. Sartorius supplies single-use bioreactors, filtration systems, cell culture media, and chromatography equipment used in the manufacture of monoclonal antibodies, vaccines, cell and gene therapies, and other biologics. Its Stedim brand, brought into the group through the acquisition of Sartorius Stedim Biotech, is widely recognised across manufacturing floors globally. The division's single-use technology portfolio has become a standard reference point for contract development and manufacturing organisations and integrated biopharma producers alike. Lab Products & Services: Precision at the Bench The Lab Products & Services division serves research and quality-control laboratories with high-precision balances, pipettes, laboratory water purification systems, and related instruments. These products carry the company's longstanding reputation for measurement accuracy, rooted in its original weighing instrument heritage. Software platforms including the Sartorius Data Intelligence suite extend the offering into digital process analytics and lab data management. Sartorius is listed on the Frankfurt Stock Exchange and is a constituent of several major European indices, reflecting its scale as a multi-billion-euro revenue business with a presence across more than 110 countries. Manufacturing and R&D sites span Europe, North America, and Asia-Pacific, with a significant operational footprint in France through its Sartorius Stedim Biotech subsidiary, which is separately listed on Euronext Paris. The company has grown substantially through acquisition as well as organic expansion, incorporating data analytics specialists such as Umetrics and BIA Separations to strengthen its digital and process chromatography capabilities. Its customer base spans early-stage biotechs through to the world's largest pharmaceutical manufacturers. Further information is available at sartorius.com.

View profile
A

Akron Biotech

Trusted by the cell and gene therapy sector since 2006, Akron Biotech supplies the ancillary materials that underpin advanced therapeutic manufacturing. Operating under the Akron Bio brand, the company occupies a specialised position in the biotech supply chain, providing the raw materials and contract services that research teams and commercial manufacturers depend on at every stage of development and scale-up. The product portfolio centres on three core categories: cytokines and growth factors, human plasma derived products, and media and media supplements. These materials are critical inputs for cell expansion, gene vector production, and the broader biomanufacturing workflows associated with advanced therapies. Alongside its catalogue offering, Akron Biotech runs dedicated manufacturing services covering proteins, media and buffers, and transfection and transduction reagents, giving clients a single source for both off-the-shelf supply and custom-manufactured components. Quality assurance is presented as a defining characteristic of the business. The company maintains regulatory support documentation and certificates for its materials, reflecting the compliance requirements of partners working in regulated therapeutic development environments. A knowledge centre comprising published posters, publications, and event resources further supports the scientific community using its products. Partnerships and collaborations form part of the company's stated commercial model, positioning Akron Biotech as an integrated supplier rather than a transactional vendor. Its leadership and newsroom functions suggest an active presence in the cell and gene therapy market rather than a passive catalogue role. Further information is available at akronbiotech.com.

View profile
C

Charles River Laboratories

Charles River Laboratories is one of the world's most recognised early-stage contract research organisations, providing the foundational scientific services that pharmaceutical and biotechnology companies rely on to move candidates from discovery through to regulatory submission. Founded in 1947 in Boston, Massachusetts, the company began as a supplier of purpose-bred laboratory animals and has since grown into a global CRO spanning drug discovery, safety assessment, and manufacturing support. Early-Stage Research & Preclinical Services The company's core strength lies in preclinical and non-clinical research. Charles River operates one of the largest networks of Good Laboratory Practice-accredited safety assessment facilities globally, conducting toxicology, pathology, and pharmacokinetic studies that satisfy regulatory requirements across the US, Europe, and Asia. Its research models business, which traces directly to its founding purpose, remains a significant operation, supplying inbred and outbred rodent models, immunocompromised strains, and specialised models to research institutions and industry clients worldwide. Discovery Services & Biologics Testing Beyond preclinical safety, Charles River has expanded substantially into integrated drug discovery services, offering medicinal chemistry, in vitro biology, and DMPK capabilities that allow clients to outsource entire lead-optimisation programmes. The company's biologics and pharmaceutical product testing division provides release testing, stability studies, and microbial safety testing for biological drugs and advanced therapies, a segment that has grown considerably as the industry has shifted toward large-molecule and cell and gene therapy pipelines. Headquartered in Wilmington, Massachusetts, and listed on the New York Stock Exchange under the ticker CRL, Charles River employs tens of thousands of scientists and support staff across more than 100 sites in approximately 20 countries. Its scale means it serves virtually every major pharmaceutical company alongside hundreds of smaller biotechnology firms and academic research centres. The company's positioning as a single-source partner for early-stage research, from target validation through to IND-enabling studies and into manufacturing quality testing, gives it a distinctive role in the global drug development supply chain. Further information is available at criver.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy